216 related articles for article (PubMed ID: 22151235)
1. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Kupert E; Anderson M; Liu Y; Succop P; Levin L; Wang J; Wikenheiser-brokamp K; Chen P; Pinney SM; Macdonald T; Dong Z; Starnes S; Lu S
BMC Cancer; 2011 Dec; 11():513. PubMed ID: 22151235
[TBL] [Abstract][Full Text] [Related]
2. Combination diagnosis of multi-slice spiral computed tomography and secretary phospholipase A2-IIa for solitary pulmonary nodules.
Hou H; Xu Z; Zhang H; Xu Y
J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28493533
[TBL] [Abstract][Full Text] [Related]
3. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
4. CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Tan TL; Ahmad NS; Nasuruddin DN; Ithnin A; Tajul Arifin K; Zaini IZ; Wan Ngah WZ
PLoS One; 2016; 11(3):e0152065. PubMed ID: 27003588
[TBL] [Abstract][Full Text] [Related]
5. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Dong Z; Meller J; Succop P; Wang J; Wikenheiser-Brokamp K; Starnes S; Lu S
Int J Oncol; 2014 Sep; 45(3):978-84. PubMed ID: 24913497
[TBL] [Abstract][Full Text] [Related]
6. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
7. Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Wang M; Hao FY; Wang JG; Xiao W
Eur Rev Med Pharmacol Sci; 2014; 18(18):2648-54. PubMed ID: 25317799
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.
Menschikowski M; Hagelgans A; Schuler U; Froeschke S; Rosner A; Siegert G
Pathol Oncol Res; 2013 Oct; 19(4):839-46. PubMed ID: 23722320
[TBL] [Abstract][Full Text] [Related]
9. [Value of Combined Detection of Cytokines and Tumor Markers in the
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
[TBL] [Abstract][Full Text] [Related]
10. Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Xin H; Chen ZY; Lv XB; Liu S; Lian ZX; Cai SL
Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):999-1004. PubMed ID: 23661511
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers.
Shen J; Liu Z; Todd NW; Zhang H; Liao J; Yu L; Guarnera MA; Li R; Cai L; Zhan M; Jiang F
BMC Cancer; 2011 Aug; 11():374. PubMed ID: 21864403
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of serum tumor markers in differentiating malignant from benign solitary pulmonary nodules].
Ni LF; Liu XM
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):707-10. PubMed ID: 25331391
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the discriminative methods for diagnosis of benign and malignant solitary pulmonary nodules based on serum markers.
Wang W; Liu M; Wang J; Tian R; Dong J; Liu Q; Zhao X; Wang Y
Oncol Res Treat; 2014; 37(12):740-6. PubMed ID: 25531720
[TBL] [Abstract][Full Text] [Related]
14. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
15. Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules.
Gu T; Wen Z; Xu S; Hua H; Zhang Z; Wen T; Fu Z; Lv X
Afr Health Sci; 2014 Jun; 14(2):356-63. PubMed ID: 25320584
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Yu JA; Mauchley D; Li H; Meng X; Nemenoff RA; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1185-91. PubMed ID: 23079010
[TBL] [Abstract][Full Text] [Related]
17. The value of macrophage inhibitory cytokine-1 level in differentiating benign from malignant solitary pulmonary nodules.
Xu CH; Xue JS; Zhang XW; Yu LK; Lin Y
Clin Respir J; 2018 Apr; 12(4):1473-1478. PubMed ID: 28834599
[TBL] [Abstract][Full Text] [Related]
18. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Tribler L; Jensen LT; Jørgensen K; Brünner N; Gelb MH; Nielsen HJ; Jensen SS
Anticancer Res; 2007; 27(5A):3179-85. PubMed ID: 17970059
[TBL] [Abstract][Full Text] [Related]
19. Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients.
Jespersen SS; Stovgaard ES; Nielsen D; Christensen TD; Buhl ASK; Christensen IJ; Balslev E
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):e5-e9. PubMed ID: 32217848
[TBL] [Abstract][Full Text] [Related]
20. Elevated Type II Secretory Phospholipase A2 Increases the Risk of Early Atherosclerosis in Patients with Newly Diagnosed Metabolic Syndrome.
Sun CQ; Zhong CY; Sun WW; Xiao H; Zhu P; Lin YZ; Zhang CL; Gao H; Song ZY
Sci Rep; 2016 Dec; 6():34929. PubMed ID: 27941821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
